Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. This multicenter, randomized phase II tr...
Uloženo v:
| Vydáno v: | Journal of clinical oncology Ročník 36; číslo 20; s. 2044 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
10.07.2018
|
| ISSN: | 1527-7755, 1527-7755 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. Methods Eligible patients had primary stage III or IV or recurrent HER2/neu-positive disease. Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. The primary end point was progression-free survival, which was assessed for differences between treatment arms via one-sided log-rank tests. Results From August 2011 to March 2017, 61 patients were randomly assigned. Forty progression-free survival-related events occurred among 58 evaluable participants. Among all patients, median progression-free survival was 8.0 months (control) versus 12.6 months (experimental; P = .005; hazard ratio [HR], 0.44; 90% CI, 0.26 to 0.76). Similarly, median progression-free survival was 9.3 (control) versus 17.9 (experimental) months among 41 patients with stage III or IV disease undergoing primary treatment ( P = .013; HR, 0.40; 90% CI, 0.20 to 0.80) and 6.0 (control) versus 9.2 months (experimental), respectively, among 17 patients with recurrent disease ( P = .003; HR, 0.14; 90% CI, 0.04 to 0.53). Toxicity was not different between treatment arms, and no unexpected safety signals emerged. Conclusion Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival. These encouraging results deserve further investigation to determine their impact on overall survival in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. |
|---|---|
| AbstractList | Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. Methods Eligible patients had primary stage III or IV or recurrent HER2/neu-positive disease. Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. The primary end point was progression-free survival, which was assessed for differences between treatment arms via one-sided log-rank tests. Results From August 2011 to March 2017, 61 patients were randomly assigned. Forty progression-free survival-related events occurred among 58 evaluable participants. Among all patients, median progression-free survival was 8.0 months (control) versus 12.6 months (experimental; P = .005; hazard ratio [HR], 0.44; 90% CI, 0.26 to 0.76). Similarly, median progression-free survival was 9.3 (control) versus 17.9 (experimental) months among 41 patients with stage III or IV disease undergoing primary treatment ( P = .013; HR, 0.40; 90% CI, 0.20 to 0.80) and 6.0 (control) versus 9.2 months (experimental), respectively, among 17 patients with recurrent disease ( P = .003; HR, 0.14; 90% CI, 0.04 to 0.53). Toxicity was not different between treatment arms, and no unexpected safety signals emerged. Conclusion Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival. These encouraging results deserve further investigation to determine their impact on overall survival in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. Methods Eligible patients had primary stage III or IV or recurrent HER2/neu-positive disease. Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. The primary end point was progression-free survival, which was assessed for differences between treatment arms via one-sided log-rank tests. Results From August 2011 to March 2017, 61 patients were randomly assigned. Forty progression-free survival-related events occurred among 58 evaluable participants. Among all patients, median progression-free survival was 8.0 months (control) versus 12.6 months (experimental; P = .005; hazard ratio [HR], 0.44; 90% CI, 0.26 to 0.76). Similarly, median progression-free survival was 9.3 (control) versus 17.9 (experimental) months among 41 patients with stage III or IV disease undergoing primary treatment ( P = .013; HR, 0.40; 90% CI, 0.20 to 0.80) and 6.0 (control) versus 9.2 months (experimental), respectively, among 17 patients with recurrent disease ( P = .003; HR, 0.14; 90% CI, 0.04 to 0.53). Toxicity was not different between treatment arms, and no unexpected safety signals emerged. Conclusion Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival. These encouraging results deserve further investigation to determine their impact on overall survival in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu.Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. Methods Eligible patients had primary stage III or IV or recurrent HER2/neu-positive disease. Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. The primary end point was progression-free survival, which was assessed for differences between treatment arms via one-sided log-rank tests. Results From August 2011 to March 2017, 61 patients were randomly assigned. Forty progression-free survival-related events occurred among 58 evaluable participants. Among all patients, median progression-free survival was 8.0 months (control) versus 12.6 months (experimental; P = .005; hazard ratio [HR], 0.44; 90% CI, 0.26 to 0.76). Similarly, median progression-free survival was 9.3 (control) versus 17.9 (experimental) months among 41 patients with stage III or IV disease undergoing primary treatment ( P = .013; HR, 0.40; 90% CI, 0.20 to 0.80) and 6.0 (control) versus 9.2 months (experimental), respectively, among 17 patients with recurrent disease ( P = .003; HR, 0.14; 90% CI, 0.04 to 0.53). Toxicity was not different between treatment arms, and no unexpected safety signals emerged. Conclusion Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival. These encouraging results deserve further investigation to determine their impact on overall survival in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. |
| Author | Abdelghany, Osama Celano, Paul Bellone, Stefania Siegel, Eric Roque, Dana M Lowery, William Silasi, Dan-Arin Fader, Amanda N Litkouhi, Babak Schwartz, Peter E Havrilesky, Laura Azodi, Masoud Santin, Alessandro D Ratner, Elena O'Malley, David M Hui, Pei Secord, Angeles Alvarez Buza, Natalia Nevadunsky, Nicole ElSahwi, Karim S Chambers, Setsuko K Edraki, Babak Backes, Floor Pikaart, Dirk |
| Author_xml | – sequence: 1 givenname: Amanda N surname: Fader fullname: Fader, Amanda N organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 2 givenname: Dana M surname: Roque fullname: Roque, Dana M organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 3 givenname: Eric surname: Siegel fullname: Siegel, Eric organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 4 givenname: Natalia surname: Buza fullname: Buza, Natalia organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 5 givenname: Pei surname: Hui fullname: Hui, Pei organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 6 givenname: Osama surname: Abdelghany fullname: Abdelghany, Osama organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 7 givenname: Setsuko K surname: Chambers fullname: Chambers, Setsuko K organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 8 givenname: Angeles Alvarez surname: Secord fullname: Secord, Angeles Alvarez organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 9 givenname: Laura surname: Havrilesky fullname: Havrilesky, Laura organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 10 givenname: David M surname: O'Malley fullname: O'Malley, David M organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 11 givenname: Floor surname: Backes fullname: Backes, Floor organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 12 givenname: Nicole surname: Nevadunsky fullname: Nevadunsky, Nicole organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 13 givenname: Babak surname: Edraki fullname: Edraki, Babak organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 14 givenname: Dirk surname: Pikaart fullname: Pikaart, Dirk organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 15 givenname: William surname: Lowery fullname: Lowery, William organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 16 givenname: Karim S surname: ElSahwi fullname: ElSahwi, Karim S organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 17 givenname: Paul surname: Celano fullname: Celano, Paul organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 18 givenname: Stefania surname: Bellone fullname: Bellone, Stefania organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 19 givenname: Masoud surname: Azodi fullname: Azodi, Masoud organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 20 givenname: Babak surname: Litkouhi fullname: Litkouhi, Babak organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 21 givenname: Elena surname: Ratner fullname: Ratner, Elena organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 22 givenname: Dan-Arin surname: Silasi fullname: Silasi, Dan-Arin organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 23 givenname: Peter E surname: Schwartz fullname: Schwartz, Peter E organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ – sequence: 24 givenname: Alessandro D surname: Santin fullname: Santin, Alessandro D organization: Amanda N. Fader, Johns Hopkins School of Medicine; Dana M. Roque, University of Maryland; Paul Celano, Greater Baltimore Medical Center, Baltimore; William Lowery, Walter Reed Medical Center, Bethesda, MD; Eric Siegel, University of Arkansas for Medical Sciences, Little Rock, AR; Natalia Buza, Pei Hui, Osama Abdelghany, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin, Yale University School of Medicine, New Haven, CT; Setsuko K. Chambers, University of Arizona, Tucson, AZ; Angeles Alvarez Secord and Laura Havrilesky, Duke University School of Medicine, Durham, NC; David M. O'Malley and Floor Backes, The Ohio State University School of Medicine, Columbus, OH; Nicole Nevadunsky, Montefiore Medical Center, Bronx, NY; Babak Edraki, John Muir Medical Center, Walnut Creek, CA; Dirk Pikaart, Penrose Cancer Center-St Francis, Colorado Springs, CO; and Karim S. ElSahwi, Meridian Health, Neptune, NJ |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29584549$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kE9PwzAMxSMEAgbcOaEcuXQkTbO2RzQxGJo0BIPr5CauFtQmJUn598n4eBQBEhdOfrLfs-zfiGxbZ5GQY87GPGXs7Hq6HKeM5-N8MpblZLJF9rlM8yTPpdz-o_fIKIRHxnhWCLlL9tJSFpnMyn3ycQtWu9a8o6Y3GwhI53O68gYa6mo6BV-5roFobHIDqjERXrGhD-hDH_6ZJisPIfbvfQsVNZbeR_TGIr1D775DyljXQqCrDUS6fEaPr53HEOjVkLH0ojMafTtccOndS9zQGajoPL1Fhd2XSM8s9odkp4Ym4NFPPSD3s4vV9CpZLC_n0_NFokTGY1JippXk9URXqmDIJat1mSmhi6GlZCUEgMpVLfNUcQmVLhFLobUAwcSQTQ_I6ffezrunHkNctyYobBqwOPyzHvCX2UCzkIP15MfaVy3qdedNC_5t_Us7_QSyioi1 |
| CitedBy_id | crossref_primary_10_1158_1078_0432_CCR_20_4436 crossref_primary_10_3390_ijms25147742 crossref_primary_10_1007_s12253_019_00675_4 crossref_primary_10_3390_cancers13122901 crossref_primary_10_1016_j_omtn_2018_08_019 crossref_primary_10_1016_j_omtn_2021_04_011 crossref_primary_10_1016_j_ygyno_2020_08_012 crossref_primary_10_1038_s41379_020_00695_5 crossref_primary_10_1016_j_clinsp_2025_100766 crossref_primary_10_1200_EDBK_280495 crossref_primary_10_1016_j_soncn_2019_02_009 crossref_primary_10_1007_s11523_020_00785_z crossref_primary_10_1016_j_humpath_2023_04_009 crossref_primary_10_1097_PGP_0000000000000812 crossref_primary_10_3390_cancers13246155 crossref_primary_10_1016_j_ygyno_2019_01_002 crossref_primary_10_1097_PAS_0000000000001682 crossref_primary_10_3802_jgo_2025_36_e93 crossref_primary_10_1200_OP_25_00017 crossref_primary_10_3390_cancers16112027 crossref_primary_10_1016_j_yao_2022_02_001 crossref_primary_10_1016_j_ygyno_2024_12_012 crossref_primary_10_1186_s12935_020_01317_5 crossref_primary_10_1007_s11912_021_01163_2 crossref_primary_10_1038_s41379_019_0358_x crossref_primary_10_1007_s11864_021_00918_0 crossref_primary_10_3390_medicina60122012 crossref_primary_10_1093_ajcp_aqac179 crossref_primary_10_1097_PGP_0000000000001115 crossref_primary_10_3390_diagnostics12081903 crossref_primary_10_1097_PGP_0000000000000943 crossref_primary_10_1016_j_ygyno_2020_05_031 crossref_primary_10_1016_j_ygyno_2024_01_013 crossref_primary_10_1158_1078_0432_CCR_21_1564 crossref_primary_10_3390_ijms25021064 crossref_primary_10_1038_s41571_025_01016_y crossref_primary_10_3390_cancers14205020 crossref_primary_10_1016_j_ctrv_2022_102500 crossref_primary_10_3390_epigenomes7040024 crossref_primary_10_1007_s00129_025_05339_w crossref_primary_10_1007_s43032_024_01544_5 crossref_primary_10_3390_ijms252212356 crossref_primary_10_1097_GCO_0000000000000832 crossref_primary_10_3390_molecules27082466 crossref_primary_10_1016_j_radonc_2020_11_018 crossref_primary_10_1111_jog_16055 crossref_primary_10_3389_fmed_2021_799163 crossref_primary_10_1007_s10555_023_10113_2 crossref_primary_10_3390_diagnostics11040717 crossref_primary_10_1016_j_ygyno_2019_05_001 crossref_primary_10_1016_j_ygyno_2025_03_011 crossref_primary_10_1016_j_ygyno_2022_05_021 crossref_primary_10_1007_s00421_025_05763_9 crossref_primary_10_1002_1878_0261_12791 crossref_primary_10_1007_s10616_025_00800_z crossref_primary_10_1038_s41568_019_0177_x crossref_primary_10_3892_mco_2025_2841 crossref_primary_10_1016_S1470_2045_19_30395_X crossref_primary_10_1097_CCO_0000000000000558 crossref_primary_10_1097_GCO_0000000000000838 crossref_primary_10_5858_arpa_2022_0229_CP crossref_primary_10_1016_j_gore_2019_04_005 crossref_primary_10_1016_j_ygyno_2023_11_021 crossref_primary_10_1016_j_ogc_2018_09_009 crossref_primary_10_1016_j_modpat_2023_100148 crossref_primary_10_3390_jcm12041480 crossref_primary_10_1016_j_gore_2021_100754 crossref_primary_10_1097_COC_0000000000000851 crossref_primary_10_1002_onco_13934 crossref_primary_10_1016_j_tjog_2025_04_007 crossref_primary_10_1200_EDBK_238755 crossref_primary_10_1016_j_gore_2020_100593 crossref_primary_10_1186_s12014_024_09451_2 crossref_primary_10_1007_s00761_019_00669_6 crossref_primary_10_1200_JCO_18_00545 crossref_primary_10_1007_s11654_022_00447_8 crossref_primary_10_1136_ijgc_2022_003806 crossref_primary_10_1097_PGP_0000000000000853 crossref_primary_10_1016_j_ygyno_2021_12_030 crossref_primary_10_1016_j_path_2022_02_006 crossref_primary_10_1016_j_ygyno_2024_05_006 crossref_primary_10_1016_j_ygyno_2020_07_016 crossref_primary_10_1016_j_humpath_2024_05_002 crossref_primary_10_1016_j_ygyno_2021_05_003 crossref_primary_10_1136_ijgc_2021_002554 crossref_primary_10_3390_cancers13246351 crossref_primary_10_1080_14656566_2022_2106782 crossref_primary_10_1016_j_humpath_2024_105649 crossref_primary_10_1097_CCO_0000000000000658 crossref_primary_10_1111_his_13704 crossref_primary_10_3390_cancers16112100 crossref_primary_10_1007_s12094_025_04046_1 crossref_primary_10_1016_S0007_4551_23_00332_6 crossref_primary_10_3390_cancers13112623 crossref_primary_10_1097_PAS_0000000000001870 crossref_primary_10_7759_cureus_89030 crossref_primary_10_1016_j_gore_2024_101462 crossref_primary_10_1111_his_14001 crossref_primary_10_1097_PGP_0000000000000864 crossref_primary_10_1093_jjco_hyaa071 crossref_primary_10_1097_PGP_0000000000000866 crossref_primary_10_3389_fonc_2023_1066427 crossref_primary_10_1111_jog_16247 crossref_primary_10_1016_j_labinv_2025_104240 crossref_primary_10_1007_s11912_021_01129_4 crossref_primary_10_1002_advs_202204211 crossref_primary_10_1016_j_ygyno_2025_02_012 crossref_primary_10_1007_s11912_019_0825_z crossref_primary_10_1016_j_mpdhp_2024_06_003 crossref_primary_10_1111_his_14015 crossref_primary_10_1155_2021_2068023 crossref_primary_10_1016_j_gore_2025_101797 crossref_primary_10_1097_PGP_0000000000000711 crossref_primary_10_3389_fonc_2023_1133277 crossref_primary_10_1016_j_modpat_2023_100299 crossref_primary_10_1097_PAS_0000000000002030 crossref_primary_10_1097_PAS_0000000000002392 crossref_primary_10_1186_s12916_025_03916_3 crossref_primary_10_3892_mco_2020_2181 crossref_primary_10_1002_jso_27717 crossref_primary_10_1136_ijgc_2020_002256 crossref_primary_10_1016_j_critrevonc_2020_103016 crossref_primary_10_1097_GCO_0000000000001055 crossref_primary_10_3390_jpm12101651 crossref_primary_10_1016_j_prp_2022_154258 crossref_primary_10_3389_fonc_2022_805613 crossref_primary_10_1016_j_ygyno_2020_10_043 crossref_primary_10_3390_cancers15194887 crossref_primary_10_1016_j_ygyno_2025_02_005 crossref_primary_10_1016_j_humpath_2025_105928 crossref_primary_10_5858_arpa_2021_0098_RA crossref_primary_10_1016_j_critrevonc_2022_103851 crossref_primary_10_1016_j_gore_2020_100561 crossref_primary_10_1097_GCO_0000000000000642 crossref_primary_10_1186_s13048_023_01235_w crossref_primary_10_1016_j_gore_2023_101194 crossref_primary_10_1080_14737140_2020_1782750 crossref_primary_10_1038_s41379_021_00746_5 crossref_primary_10_1200_JCO_18_02037 crossref_primary_10_1007_s00428_021_03017_5 crossref_primary_10_1016_j_bulcan_2020_06_006 crossref_primary_10_1016_j_hpr_2024_300764 crossref_primary_10_1038_s41379_022_01102_x crossref_primary_10_1016_j_ijgc_2025_101672 crossref_primary_10_1097_PGP_0000000000000725 crossref_primary_10_1097_PGP_0000000000000966 crossref_primary_10_3390_cancers11070964 crossref_primary_10_1002_dc_25449 crossref_primary_10_1111_his_14381 crossref_primary_10_12998_wjcc_v11_i23_5447 crossref_primary_10_1016_j_gore_2020_100554 crossref_primary_10_1016_j_gaitpost_2022_04_002 crossref_primary_10_1016_j_prro_2019_02_007 crossref_primary_10_1007_s00129_022_04979_6 crossref_primary_10_1007_s00428_020_03007_z crossref_primary_10_1016_j_gore_2020_100555 crossref_primary_10_3390_cancers11111665 crossref_primary_10_1016_j_critrevonc_2024_104555 crossref_primary_10_3390_cancers13215257 crossref_primary_10_3390_ijms19082380 crossref_primary_10_1016_j_ygyno_2021_08_014 crossref_primary_10_1016_j_path_2021_05_012 crossref_primary_10_1016_j_ygyno_2019_11_018 crossref_primary_10_1136_ijgc_2021_002753 crossref_primary_10_3390_jcm13082158 crossref_primary_10_1097_PGP_0000000000000774 crossref_primary_10_1177_17588359211035959 crossref_primary_10_1136_ijgc_2020_001822 crossref_primary_10_3390_cancers16071346 crossref_primary_10_3390_cells14161282 crossref_primary_10_1016_j_gore_2020_100549 crossref_primary_10_1007_s11912_021_01073_3 crossref_primary_10_1136_ijgc_2020_002230 crossref_primary_10_1159_000547372 crossref_primary_10_1002_hc_21436 crossref_primary_10_1053_j_semdp_2021_10_006 crossref_primary_10_1016_j_ygyno_2022_02_003 crossref_primary_10_1038_s41572_021_00324_8 crossref_primary_10_1016_j_ygyno_2024_06_024 crossref_primary_10_1002_ijgo_13866 crossref_primary_10_1016_j_gore_2023_101250 crossref_primary_10_1097_PGP_0000000000000780 crossref_primary_10_1016_j_semcancer_2023_09_005 crossref_primary_10_1097_PGP_0000000000000783 crossref_primary_10_1007_s00428_023_03640_4 crossref_primary_10_1038_s41392_024_01760_0 crossref_primary_10_1097_PAI_0000000000001144 crossref_primary_10_1016_j_bulcan_2023_07_005 crossref_primary_10_1136_ijgc_2022_003673 crossref_primary_10_1097_AOG_0000000000006080 crossref_primary_10_1016_j_anndiagpath_2023_152173 crossref_primary_10_1016_j_ygyno_2023_05_059 crossref_primary_10_1158_1078_0432_CCR_18_0864 crossref_primary_10_1016_j_ygyno_2018_05_015 crossref_primary_10_1186_s12967_023_04264_7 crossref_primary_10_3322_caac_21561 crossref_primary_10_1016_j_ygyno_2024_10_015 crossref_primary_10_1136_ijgc_2024_005295 crossref_primary_10_1007_s11033_023_08580_5 crossref_primary_10_1016_j_isci_2025_112850 crossref_primary_10_3390_genes12101593 crossref_primary_10_1016_j_ygyno_2020_02_015 crossref_primary_10_1097_AOG_0000000000005307 crossref_primary_10_1016_j_ygyno_2020_10_017 crossref_primary_10_1016_j_ygyno_2020_10_018 crossref_primary_10_5306_wjco_v12_i10_868 crossref_primary_10_1016_j_ctarc_2022_100631 crossref_primary_10_3390_ijms25115893 crossref_primary_10_7759_cureus_67332 crossref_primary_10_1136_ijgc_2024_005607 crossref_primary_10_1016_j_ygyno_2021_04_029 crossref_primary_10_1186_s12885_023_11382_4 crossref_primary_10_1002_1878_0261_13346 crossref_primary_10_1097_PGP_0000000000000756 crossref_primary_10_7759_cureus_26663 crossref_primary_10_1016_j_ygyno_2022_09_006 crossref_primary_10_1136_ijgc_2021_003144 crossref_primary_10_1056_NEJMra1514010 crossref_primary_10_1177_10668969221102529 crossref_primary_10_1186_s13046_025_03406_7 crossref_primary_10_1002_1878_0261_12813 crossref_primary_10_1080_14728222_2024_2316739 crossref_primary_10_3390_cancers16183145 crossref_primary_10_5858_arpa_2023_0098_RA crossref_primary_10_1038_s41417_020_0164_0 crossref_primary_10_1200_JCO_19_00037 crossref_primary_10_1016_j_tjog_2024_03_034 crossref_primary_10_1097_PGP_0000000000001050 crossref_primary_10_1200_EDBK_351294 crossref_primary_10_1097_MD_0000000000039957 crossref_primary_10_5858_arpa_2022_0467_RA crossref_primary_10_1186_s40364_021_00301_z crossref_primary_10_3390_cancers13163988 crossref_primary_10_1186_s12885_024_13226_1 crossref_primary_10_1007_s00428_024_03874_w crossref_primary_10_3390_cancers13081900 crossref_primary_10_1016_j_ijgc_2025_101758 crossref_primary_10_7759_cureus_71497 crossref_primary_10_1016_j_pharmthera_2019_03_010 crossref_primary_10_1097_PGP_0000000000001059 crossref_primary_10_1016_j_clinthera_2023_07_025 crossref_primary_10_3390_cells14171404 crossref_primary_10_1016_j_tjog_2025_04_001 crossref_primary_10_1007_s11864_023_01169_x crossref_primary_10_3390_ijms25021201 crossref_primary_10_1158_1078_0432_CCR_23_3689 crossref_primary_10_1080_14656566_2022_2157207 crossref_primary_10_1080_14737140_2024_2370377 crossref_primary_10_1016_j_gore_2022_100995 crossref_primary_10_1371_journal_pone_0264014 crossref_primary_10_18027_2224_5057_2023_13_2_6 crossref_primary_10_3390_cancers15164085 crossref_primary_10_1158_1078_0432_CCR_20_0953 crossref_primary_10_1016_j_annonc_2022_05_009 crossref_primary_10_1097_PGP_0000000000000690 crossref_primary_10_1111_jog_16197 crossref_primary_10_36290_xon_2024_005 crossref_primary_10_1016_j_ijgc_2025_102115 crossref_primary_10_1200_EDBK_25_473114 crossref_primary_10_1016_j_ygyno_2025_05_004 crossref_primary_10_1073_pnas_2206751120 crossref_primary_10_1200_PO_24_00815 crossref_primary_10_1016_j_gore_2023_101219 crossref_primary_10_1007_s11912_022_01327_8 crossref_primary_10_1002_jcph_1382 crossref_primary_10_1093_jnci_djae277 crossref_primary_10_1038_s41598_020_58009_3 crossref_primary_10_3390_cancers16040770 crossref_primary_10_1158_2159_8290_CD_19_1014 crossref_primary_10_1177_17588359211001199 crossref_primary_10_3389_fimmu_2024_1349033 crossref_primary_10_1097_PGP_0000000000000585 crossref_primary_10_1371_journal_pone_0257976 crossref_primary_10_1016_j_ijgc_2025_101934 crossref_primary_10_1186_s12885_023_11793_3 crossref_primary_10_5858_arpa_2022_0280_RA crossref_primary_10_1016_j_ygyno_2020_12_021 crossref_primary_10_1016_j_ygyno_2020_12_024 crossref_primary_10_1002_1878_0261_13698 crossref_primary_10_3390_curroncol32060340 crossref_primary_10_1016_j_cll_2023_08_013 crossref_primary_10_1016_j_ygyno_2025_05_017 crossref_primary_10_1097_PGP_0000000000000901 crossref_primary_10_1111_his_15170 crossref_primary_10_1186_s12920_020_00824_8 crossref_primary_10_1002_cjp2_184 crossref_primary_10_1038_s41379_021_00997_2 crossref_primary_10_3390_jcm9061900 crossref_primary_10_5858_arpa_2021_0547_OA crossref_primary_10_1002_cncr_35381 crossref_primary_10_1016_j_ygyno_2021_07_033 crossref_primary_10_1016_j_ygyno_2022_10_012 crossref_primary_10_1016_j_ygyno_2021_02_015 crossref_primary_10_1002_jso_27552 crossref_primary_10_1097_GCO_0000000000000599 crossref_primary_10_1016_j_ygyno_2023_12_028 crossref_primary_10_1016_j_pathol_2022_11_004 crossref_primary_10_1038_s41571_024_00924_9 crossref_primary_10_1093_ajcp_aqad056 crossref_primary_10_3390_cancers12030686 crossref_primary_10_1177_2050313X221081361 crossref_primary_10_1177_17588359221112822 crossref_primary_10_1016_j_microc_2025_114643 crossref_primary_10_1016_j_ygyno_2018_07_013 crossref_primary_10_5858_arpa_2020_0207_RA crossref_primary_10_1016_j_ygyno_2020_09_003 crossref_primary_10_1080_21678707_2020_1784723 crossref_primary_10_1038_s41379_020_0627_8 crossref_primary_10_1007_s00292_021_00933_w crossref_primary_10_1007_s11864_025_01345_1 crossref_primary_10_3390_cancers13235877 crossref_primary_10_1016_j_critrevonc_2023_103997 crossref_primary_10_3390_cancers13010044 crossref_primary_10_1136_ijgc_2022_004073 crossref_primary_10_1159_000542359 crossref_primary_10_1016_j_bpobgyn_2021_06_002 crossref_primary_10_1016_j_ygyno_2022_04_014 crossref_primary_10_1016_j_ijgc_2025_101948 crossref_primary_10_1007_s11864_022_00993_x crossref_primary_10_1007_s12672_024_01344_y crossref_primary_10_12688_f1000research_17408_1 crossref_primary_10_1007_s40142_020_00192_w crossref_primary_10_3390_cancers13225848 crossref_primary_10_1038_s41420_022_01005_5 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1200/JCO.2017.76.5966 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 29584549 |
| Genre | Journal Article |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP ABBLC ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL BYPQX C45 CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YFH YQY 7X8 |
| ID | FETCH-LOGICAL-c341t-9e4dc51f6dbc80e150fd94c3d8f6dc5b33aac7cf572c15abd9ee93dd3a303e4d2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 366 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000438020500006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Wed Oct 01 12:11:34 EDT 2025 Mon Jul 21 06:02:15 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 20 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c341t-9e4dc51f6dbc80e150fd94c3d8f6dc5b33aac7cf572c15abd9ee93dd3a303e4d2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://repository.arizona.edu/bitstream/10150/631014/1/jco.2017.76.5966.pdf |
| PMID | 29584549 |
| PQID | 2019458485 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2019458485 pubmed_primary_29584549 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-07-10 20180710 |
| PublicationDateYYYYMMDD | 2018-07-10 |
| PublicationDate_xml | – month: 07 year: 2018 text: 2018-07-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2018 |
| SSID | ssj0014835 |
| Score | 2.6777442 |
| Snippet | Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2044 |
| Title | Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29584549 https://www.proquest.com/docview/2019458485 |
| Volume | 36 |
| WOSCitedRecordID | wos000438020500006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEF_UivjiR7VavxhB-tRt7y632d0nkaOnFXsNcoV7O_ZjFg_a5LzktO1f5p_n7CblXhQEX0KSZWHCTOZ758fYO5kTV30I3JL-pwBFaW6tDdw4JXKrlPaYDgp_kZOJms100SXc6q6t8kYnJkXtKxdz5BSkU7hN1lKJ98vvPKJGxepqB6Fxm21l5MpEqZazTRVhqBLAZkRuJS9SiK5MSYJx-Hl0Gvu65IHMD4TuZiT-0cFMhmb88H9JfMQedC4mfGhl4jG7heU2u3fSFdG32V7Rjqu-2ofp5vRVvQ97UGwGWV89Yb--mtJXF4tr9HGlRjg-hmmUWKgCjMzKVsvYSlfywrg47PsSzyEm4Nb1X1Y5mca6WV-vL4yFRQlnTTp9CKSxqnYTkRg7logy08Ap_Wd4mVp1IVUb4CgC2hKJ5_BxVf1svsE44QUBeb-4jDeDwxLXT9nZ-Gg6-sQ7pAfuyIo2XOPQO9EPubdO9ZCc1OD10GVe0SsnbJYZ46QLQg5cXxjrNaLOvM8MWWDaO9hhd8qqxOcMgu4ZHXLtJSKFutI44jKSU-u917nMdtnbG-bN6U-K5RFTIn3jfMO-XfaslYD5sh35MR9oWqBQ-sU_7H7J7tODigngfu8V2wqkR_A1u-t-NIt69SaJKF0nxclviV72gA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized+Phase+II+Trial+of+Carboplatin-Paclitaxel+Versus+Carboplatin-Paclitaxel-Trastuzumab+in+Uterine+Serous+Carcinomas+That+Overexpress+Human+Epidermal+Growth+Factor+Receptor+2%2Fneu&rft.jtitle=Journal+of+clinical+oncology&rft.au=Fader%2C+Amanda+N&rft.au=Roque%2C+Dana+M&rft.au=Siegel%2C+Eric&rft.au=Buza%2C+Natalia&rft.date=2018-07-10&rft.eissn=1527-7755&rft.volume=36&rft.issue=20&rft.spage=2044&rft_id=info:doi/10.1200%2FJCO.2017.76.5966&rft_id=info%3Apmid%2F29584549&rft_id=info%3Apmid%2F29584549&rft.externalDocID=29584549 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |